Marcie Rabin, MD
Neurology · Summit, NJNPI 1750445680
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $329,006 of the $387,152 with a category attached, or 85.0%. Teva Pharmaceuticals USA, Inc. accounts for 62.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $127,800 and has fallen 71.3% since, to $36,675 in 2025. Among neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 544 payments — averaging $711.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$240K
- AbbVie$120K
- Merz North America, Inc.$13K
- Merz Pharmaceuticals, LLC$11K
- Boston Scientific$793
- Abbott$722
- plus $1K from 18 others
What the payments were for
- Consulting fees$18,8315%
- Speaking & faculty fees$329,00685%
- Travel & lodging$26,9447%
- Food & beverage$12,2593%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 260 | $240,379 |
| AbbVie(2 entities) | 158 | $120,063 |
| Merz North America, Inc. | 16 | $12,874 |
| Merz Pharmaceuticals, LLC | 18 | $10,885 |
| Boston Scientific | 28 | $793 |
| Abbott | 18 | $722 |
| Medtronic(2 entities) | 9 | $385 |
| EDW Pharma, Inc. | 1 | $320 |
| MDD US Operations, LLC | 15 | $198 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Amgen | 1 | $103 |
| EMD Serono, Inc. | 3 | $42 |
| Ipsen Biopharmaceuticals, Inc | 3 | $40 |
| Kyowa Kirin, Inc. | 2 | $35 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Insightec,inc | 1 | $24 |
| Novartis | 1 | $21 |
| GE HealthCare | 1 | $20 |
| Pfizer | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$135,623
- BOTOX$107,533
- Austedo XR$102,806
- XEOMIN$23,439
- UBRELVY$10,453
- Tiglutik$320
- INFINITY$227
- PERCEPT PC BRAINSENSE$133
- ZEPOSIA$125
- GENERAL DBS$125
- UZEDY$106
- UPLIZNA$103
How this compares
$387,152 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 45 | $103,364 |
| AustedoDeutetrabenazine | 13 | $91,931 |
| XeominIncobotulinumtoxina | 18 | $23,120 |
| RytaryCarbidopa/Levodopa | 16 | $19,742 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 205 | $10,055 |
| Rasagiline Mesylate | 24 | $6,459 |
| AmantadineAmantadine Hcl | 65 | $4,966 |
| Selegiline Hcl | 41 | $3,342 |
| Gabapentin | 35 | $1,137 |
| Propranolol Hcl | 24 | $861 |
| Clonazepam | 35 | $619 |
| Primidone | 20 | $615 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 17 | $408 |
| Baclofen | 18 | $249 |
| Escitalopram Oxalate | 11 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $120,063 | $103,36445 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $240,379 | $91,93113 claims |
| Merz North America, Inc.Xeomin | $12,874 | $23,12018 claims |
| Amneal Pharmaceuticals LLCRytary | $28 | $19,74216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 521 neurology providers in New Jersey.
Other neurology in Summit
- Nicholas MetrusSummit$49K
- Seth StollerSummit$35K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Ashish KapoorBayonne$329K
- Mario VukicHackensack$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.